Back to resultsErythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Primary Purpose
Heart Failure
Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
erythropoietin
Sponsored by
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Ischemic heart disease
- Systolic lv dysfunction
- Mild anemia
- Normal renal function
- Stable condition
Exclusion Criteria:
- Pregnancy
- Unstable condition
- Under 18 years old
Sites / Locations
- Cardiology Department, Rabin Medical Center
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00418119
Brief Title
Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Official Title
Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Study Type
Interventional
2. Study Status
Record Verification Date
December 2006
Overall Recruitment Status
Unknown status
Study Start Date
January 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2008 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Rabin Medical Center
4. Oversight
5. Study Description
Brief Summary
Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
erythropoietin
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ischemic heart disease
Systolic lv dysfunction
Mild anemia
Normal renal function
Stable condition
Exclusion Criteria:
Pregnancy
Unstable condition
Under 18 years old
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tuvia Ben Gal, MD
Phone
972-522757616
Email
bengalt@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Murninkas, MD
Phone
972-39376930
Email
murninkasd@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tuvia Ben Gal, MD
Organizational Affiliation
Cardiology Department Rabin medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ofer Shpilberg, Prof.
Organizational Affiliation
Hematology Department Rabin Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Daniel Murninkas, MD
Organizational Affiliation
Cardiology Department Rabin Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Cardiology Department, Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tuvia Ben Gal, MD
Phone
972-522757616
Email
bengalt@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Daniel Murninkas, MD
Phone
972-39736930
Email
murninkasd@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Tuvia Ben Gal, MD
First Name & Middle Initial & Last Name & Degree
Ofer Shpilberg, Prof.
First Name & Middle Initial & Last Name & Degree
Daniel Murninkas, MD
12. IPD Sharing Statement
Learn more about this trial
Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
We'll reach out to this number within 24 hrs